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OBJECTIVE
•

This study was conducted to evaluate the patient landscape of IVIG use
within our community health system, both before and after protocol
implementation. Our goals were to identify potential changes with the
indication for use along with any prescribed dosing decreases while under
protocol.

BACKGROUND
• Intravenous Immunoglobulin (IVIG) serves as a therapeutic option for a
variety of disease states which stem
from immunodeficiency or
inflammatory reactions.1
• IVIG currently holds 7 different FDA-approved indications; however, there
are many off-label uses of IVIG with varying levels of clinical evidence and
proven efficacy.1
• Standard dosing of IVIG varies by indication, ranging from 0.2-2 g/kg.
Dosing weight for IVIG has traditionally been actual body weight (ABW);
however, ideal body weight (IBW) dosing has demonstrated noninferiority.1
• The U.S. market currently reports over 5.9 billion dollars in total cost from
IVIG utilization with projections of an annual 6.8% increase in cost through
2028.2
• With IVIG shortages as a continual concern, IBW IVIG dosing restrictions
serve as a viable solution to minimize over utilization, immunoglobulin
waste, and inflated market demands.

METHODS
• Retrospective, system-wide, cohort study comparing two separate 18month periods spanning from January 2018 to June 2019 and July 2019 to
December 2020.
• Parkview Health System implemented a restrictive dosing and indication
protocol for use of IVIG starting in July of 2019.
• The patient population consisted of both inpatient (IP) and outpatient (OP)
hospital-based infusion clinics who had EHR documentation of IVIG
administrations.
• The first group represented standard pre-protocol utilization of IVIG (preprotocol), whereas the second group was dictated by our hospital’s
restrictive use policy (post-protocol).
• The following data was obtained for each patient encounter: age, height,
weight, gender, associated diagnosis, and total dose/day.
• Patients were additionally grouped by inpatient or outpatient
setting, ordering provider specialties, and grouped diagnoses.
• Diagnoses were grouped into the following categories: primary
immunodeficiency, other immunodeficiency, neuroimmunologic disorders,
neuromuscular junction syndromes, immune thrombocytopenia, nonimmune thrombocytopenia, autoimmune skin conditions, miscellaneous,
other autoimmune diseases, and infection-related diseases.
• All data was extracted from the electronic health record (EHR) and
manually validated. The data was evaluated via descriptive statistics.

RESULTS

RESULTS
• Neurology and oncology provider specialties saw the greatest number
of patient administrations in the IP setting (pre: 161, 98 post: 149, 95)
respectively.
• Neurology and allergy/immunology provider specialties saw the greatest
number of patient administrations in the OP setting
(pre: 247, 397 post: 436, 473) respectively.
• Pricing was evaluated using a standardized product (Gammagard 10%) due
to a wide variation of IVIG brand utilization during the post-protocol product
shortage.
• Average Wholesaler Price (AWP) per gram of 100 mL of Gammagard 10%
was $239.24 as of August 2021.3
• Basing the AWP price for Gammagard 10% on observed dosing decreases in
the inpatient setting, potential cost savings per administered IVIG dose are
$1,100.50.
• This value is highly dependent upon location, provider adherence to dosing
and prescribing recommendations, and indication of patients.

DISCUSSION & CONCLUSIONS
• We expected to observe a decrease in total grams of IVIG utilization between
pre- and post-protocol populations but saw an increase in overall use and
administrations.
• The overall average dose was slightly lower but was more prominent after
separating inpatient, acute use from outpatient, chronic use.
• Due to limitations with defining a single, specific associated diagnosis or
indication, no specific conclusions can be drawn on potential impact to
specific disease states or areas.
• Chronic-use IVIG patients are typically seen in the OP setting and tend to be
stable on a previously determined regimen, so dose decreases under new
dosing protocols are unlikely in the OP setting. This was confirmed in our
review as the average total dose was similar in the pre- and postprotocol outpatient doses.
• Best application is in the inpatient setting with greater chance for protocol
adherence/implementation.
• General medicine, oncology, neurology, and emergent care are locations with
the greatest utilization of IVIG and greatest opportunity for dosing
optimization.
• The use of IVIG restriction protocols has the potential for major cost-savings
and the avoidance of overutilization specifically in the inpatient setting;
however, success is highly dependent upon provider dosing adjustments
and adherence.
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